and in the US manufacturers of branded drugs have become adept at constructing patent defences to prevent competition. The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Deemed as the “drug that changed the breast cancer treatment landscape,” Herceptin has saved millions of women's lives ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...